BBK Worldwide Blog

More of Your Questions Answered

In this special video clip, industry innovators Aaron Fleishman and Craig Lipset answer some of the overflow questions from our Virtual Town Hall on maintaining clinical trial momentum during COVID-19 and beyond.

This 20-minute segment features answers to your questions relating to:

• Implementation of decentralized trials
• Impact of COVID-19 on enrollment of healthy volunteers
• Biggest concerns for clinicians around remote contact with patients
• Advancing decentralized trials while not leaving behind people without access to reliable internet, electronic devices, or digital savvy
• Validating new digital endpoints for decentralized trials
• Impact of telemedicine and other decentralized trial approaches on  monitoring and source data verification (SDV)

Driven by audience questions, industry innovators Aaron Fleishman and Craig Lipset discuss maintaining clinical trial momentum during COVID-19 and beyond during our recent virtual town hall.

Watch now to gain insight into overcoming patient enrollment and engagement challenges while supporting study continuity. Learn how to minimize clinical trial disruption with solutions for all stages of study activity – planning, enrolling, and even restarting.

"COVID-19 and Beyond" Virtual Town Hall - May 14, 2020 @ 12:00 p.m. ET

Join industry innovators Craig Lipset and Aaron Fleishman for a virtual town hall to discuss maintaining clinical trial momentum during COVID-19 and beyond. Register now.

If you attended our recent webinar “Harnessing the Power of mHealth for New, Better Data and Improved Patient Engagement” you had the opportunity to submit a question to BBK Worldwide^® President Matt Kibby or Roche Operational Intelligence Leader, Lewis Millen, during the webinar’s Q&A portion. We received so many great and thoughtful questions from our attendees, that we were, unfortunately, unable to address all of them. Today, we are happy to share Matt’s responses to many of those questions here, and we hope you find his answers useful.

During last week’s webinar with BBK President Matt Kibby and Roche’s Operational Intelligence Leader, Lewis Millen, on “Harnessing the Power of mHealth for New, Better Data and Improved Patient Engagement,” we had the opportunity to cover a variety of topics and challenges related to mHealth adoption and deployment. And we were pleased to have so many representatives from all areas of clinical R&D, including patients, join us. Lewis was able to provide such valuable insights and if you joined us, you know that first hand.

At BBK Worldwide^® we are committed to improving patient engagement through patient-centric technologies and best-practices. Alongside our clinical research partners, we work to boost clinical trial awareness and simplify the clinical trial experience for patients and sites. As the healthcare industry reaffirms its commitment to improving the pathways to improved clinical research, BBK will host Harnessing the Power of mHealth for New, Better Data and Improved Patient Engagement, a webinar to discuss what's needed to leverage the power of mHealth and related technologies to the benefit of the study and the study patient on Friday, October 28, 2016 at 12:00 p.m. ET.

Late last month, BBK Worldwide^® hosted the webinar Rare Disease 20/20: A Look at the Challenges and Opportunities in Rare Disease Clinical R&D giving our listeners the opportunity to gain insights from thought leaders in rare disease patient advocacy and orphan drug development.

To raise awareness with policy makers and the public of rare diseases and of their impact on the lives of patients and their loved ones, the National Organization for Rare Disorders (NORD) established Rare Disease Day® in the U.S. almost seven years ago. Since then, people all over the world have come together to inform the public and engage with policy makers, researchers, health professionals and more, affecting positive change for all those impacted by rare diseases.

Mobile devices and apps which monitor vital signs, analyze blood, and track medication adherence, among other things are quickly becoming the new norm in healthcare. But how is mHealth making its mark on clinical trials? A recent survey conducted by Applied Clinical Trials and SCORR Marketing confirms that mobile health technology is in fact poised to improve data collection and quality, and drive efficiencies across the clinical trial landscape.